Cargando…
Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy
The absence of the dystrophin protein in Duchenne muscular dystrophy (DMD) results in myofiber fragility and a plethora of downstream secondary pathologies. Although a variety of experimental therapies are in development, achieving effective treatments for DMD remains exceptionally challenging, not...
Autores principales: | van Westering, Tirsa L. E., Johansson, Henrik J., Hanson, Britt, Coenen-Stass, Anna M. L., Lomonosova, Yulia, Tanihata, Jun, Motohashi, Norio, Yokota, Toshifumi, Takeda, Shin'ichi, Lehtiö, Janne, Wood, Matthew J. A., EL Andaloussi, Samir, Aoki, Yoshitsugu, Roberts, Thomas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710136/ https://www.ncbi.nlm.nih.gov/pubmed/32994316 http://dx.doi.org/10.1074/mcp.RA120.002345 |
Ejemplares similares
-
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019) -
Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2015) -
Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013) -
Development of Therapeutic RNA Manipulation for Muscular Dystrophy
por: Saifullah,, et al.
Publicado: (2022) -
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)